Literature DB >> 18091516

Is the corrected-creatinine model for end-stage liver disease a feasible strategy to adjust gender difference in organ allocation for liver transplantation?

Samantha C Huo1, Teh-Ia Huo, Han-Chieh Lin, Chin-Wen Chi, Pui-Ching Lee, Fan-Wei Tseng, Shou-Dong Lee.   

Abstract

BACKGROUND: The Model for End-stage Liver Disease (MELD) scoring system is used for organ allocation in liver transplantation. Female cirrhotic patients have lower glomerular filtration rates (GFR) than males for the same creatinine (Cr) level. Correcting the Cr in females for the same GFR as in males shows that females have lower MELD scores and therefore a lower priority for liver transplantation; however, there has been no outcome data that justifies this modification.
METHODS: We investigated 472 cirrhotic patients, comparing the mortality rate between males and females in relation to MELD and corrected-Cr MELD.
RESULTS: Compared to females, male patients had a higher MELD (14.5+/-5.5 vs. 13.8+/-5.7) and significantly higher GFR (61.7+/-21.4 vs. 54.7+/-25.6 mlLmin/1.73 m, P=0.0002) because their Cr value was higher (1.4+/-0.4 vs. 1.3+/-0.5 mg/dL, P=0.0002). The corrected-Cr MELD score in females was higher (15.7+/-6.3) compared to the MELD in their original counterpart (P<0.0001) and the males (P=0.060). Female and male patients had a similar 3-month mortality rate (6.7% vs. 6.3%) and MELD (21.9+/-8.6 vs. 21.7+/-8.9) among deceased patients. At 6 months, female patients tended to have a lower mortality (12.5% vs. 14.7%) and a lower MELD (18.9+/-7.7 vs. 19.4+/-8.5) in deceased patients. However, at 9 and 12 months, females had a consistently higher mortality (25% vs. 21.2% and 37.5% vs. 31.3%, respectively) but lower MELD scores than males by 0.3-1 point.
CONCLUSIONS: Using corrected-Cr MELD, which would prioritize female patients for liver transplantation, may only be justified in predicting intermediate-term (9- and 12-month), but not short-term (3- and 6-month) mortality.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18091516     DOI: 10.1097/01.tp.0000282867.92367.d0

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  15 in total

Review 1.  Prioritization for liver transplantation.

Authors:  Evangelos Cholongitas; Giacomo Germani; Andrew K Burroughs
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-02       Impact factor: 46.802

2.  Reduced Access to Liver Transplantation in Women: Role of Height, MELD Exception Scores, and Renal Function Underestimation.

Authors:  Alina M Allen; Julie K Heimbach; Joseph J Larson; Kristin C Mara; W Ray Kim; Patrick S Kamath; Terry M Therneau
Journal:  Transplantation       Date:  2018-10       Impact factor: 4.939

Review 3.  Gender-based disparities in access to and outcomes of liver transplantation.

Authors:  Omobonike O Oloruntoba; Cynthia A Moylan
Journal:  World J Hepatol       Date:  2015-03-27

Review 4.  Model for End-stage Liver Disease.

Authors:  Ashwani K Singal; Patrick S Kamath
Journal:  J Clin Exp Hepatol       Date:  2012-12-01

5.  Shorter Height Is Associated With Lower Probability of Liver Transplantation in Patients With Hepatocellular Carcinoma.

Authors:  Eric Lee; Monika Sarkar; Jennifer Dodge; Maureen Kohi; Neil Mehta
Journal:  Transplantation       Date:  2020-05       Impact factor: 4.939

6.  Height contributes to the gender difference in wait-list mortality under the MELD-based liver allocation system.

Authors:  J C Lai; N A Terrault; E Vittinghoff; S W Biggins
Journal:  Am J Transplant       Date:  2010-11-18       Impact factor: 8.086

7.  Gender-Specific Differences in Baseline, Peak, and Delta Serum Creatinine: The NACSELD Experience.

Authors:  Jacqueline G O'Leary; Florence Wong; K Rajender Reddy; Guadalupe Garcia-Tsao; Patrick S Kamath; Scott W Biggins; Michael B Fallon; Ram M Subramanian; B Maliakkal; Leroy Thacker; Jasmohan S Bajaj
Journal:  Dig Dis Sci       Date:  2016-12-26       Impact factor: 3.199

8.  Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis.

Authors:  Ayse L Mindikoglu; Antone R Opekun; William E Mitch; Laurence S Magder; Robert H Christenson; Thomas C Dowling; Matthew R Weir; Stephen L Seliger; Charles D Howell; Jean-Pierre Raufman; Abbas Rana; John A Goss; Saira A Khaderi; John M Vierling
Journal:  Dig Dis Sci       Date:  2018-02-01       Impact factor: 3.199

9.  Revision of MELD to include serum albumin improves prediction of mortality on the liver transplant waiting list.

Authors:  Robert P Myers; Abdel Aziz M Shaheen; Peter Faris; Alexander I Aspinall; Kelly W Burak
Journal:  PLoS One       Date:  2013-01-18       Impact factor: 3.240

10.  Correcting the sex disparity in MELD-Na.

Authors:  Nicholas L Wood; Douglas VanDerwerken; Dorry L Segev; Sommer E Gentry
Journal:  Am J Transplant       Date:  2021-07-12       Impact factor: 9.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.